Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 4, 2009
Event: Receipt of conditional FDA approval to commence the ENTRUST Trial for the TAArget Thoracic Stent Graft.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a regulatory event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the regulatory status of the TAArget Thoracic Stent Graft:
- Regulatory Milestone: On December 4, 2009, the Company received conditional approval from the FDA to begin the ENTRUST Trial, a feasibility study for the TAArget Thoracic Stent Graft.
- Condition: Approval is contingent upon the Company resolving specific issues identified in the FDA's conditional approval letter to the agency's satisfaction.
- Study Scope: The trial intends to enroll 30 patients across up to four centers with a six-month follow-up period.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- The Company intends to work with the FDA to resolve outstanding issues to fully approve the Investigational Device Exemption (IDE).
- Upon successful completion of the six-month follow-up, the Company plans to apply for an IDE supplement to conduct a pivotal study supporting a potential Premarket Application (PMA).
- The study compares the device against open surgical thoracic aorta repair, focusing on endoleak, aneurysm size change, device migration, and major adverse events.
Risks and Contingencies:
- Regulatory Risk: No assurance exists that the FDA will fully approve the IDE or that the device will be approved for sale in the United States.
- Clinical Risk: Results of the ENTRUST Trial may be unfavorable or may not be accepted by the FDA even if favorable.
- Commercialization Risk: Uncertainty regarding the ability to successfully commercialize the device if approved.
Investor Verification Checklist
- Verify the specific issues identified in the FDA's conditional approval letter that must be resolved.
- Monitor the timeline for the resolution of FDA issues and the actual start date of patient enrollment.
- Review the Company's Annual Report on Form 10-K for detailed risk factors and financial health not included in this 8-K.
- Track the enrollment progress of the 30-patient target and the six-month follow-up data.